Pfizer lifts 2021 forecasts, sees $36 bn in Covid-19 vaccine sales

NEW YORK: Pfizer again lifted its 2021 profit and revenue outlook on Tuesday, bolstered by the latest surge in Covid-19 vaccinations, including regulatory approvals for boosters and shots for younger populations.
The drugmaker now expects 2.3 billion dosage deliveries of the Covid-19 vaccine in 2021, up 200 million from its previous forecast in July. That will bring total 2021 revenues for the vaccine to $36 billion, from $33.5 billion.
Pfizer said higher forecast 2021 earnings and sales effects the performance of the Covid-19 vaccine, as well as Pfizer's broader business.